shelf(0)

No. 016 · GH & Growth · Growth Hormone

MOD-GRF (1-29)

Modified GRF (1-29)CJC-1295 without DACTetrasubstituted GRF(1-29)

C Tier C · Animal data how tiers work →
  • Not FDA approved
  • WADA ✗ S2
Compare Cite
Fingerprint no sequence
MOD-GRF (1-29) (no defined sequence)

No sequence on file. We only draw fingerprints from published sequences — this ring motif is a placeholder, never a guessed sequence.

01

Evidence

  1. D In vitro
  2. C Animal
  3. B Human pilot
  4. A RCT
  5. S Approved

TIER C — Evidence comes mostly from animal studies.

Published data are mostly preclinical; no completed human trials of this compound were found.

Tiers rate the strength of published evidence — not effectiveness, safety, or a recommendation.

02

At a glance

Routes studied
Subcutaneous, Intramuscular Routes used in published research
FDA
Not approved
WADA
Prohibited · S2 Peptide hormones, growth factors, related substances and mimetics
03

Overview

A modified growth hormone releasing factor with four amino acid substitutions for improved stability and bioavailability. Functionally equivalent to CJC-1295 without DAC.

Research status Extensive research as tetrasubstituted GRF(1-29); well-characterized pharmacokinetics

04

Mechanism

MOD-GRF (1-29) is tetrasubstituted GRF(1-29) with amino acid replacements at positions 2, 8, 15, and 27 to resist enzymatic degradation. It binds the GHRH receptor and activates adenylyl cyclase/cAMP signaling in pituitary somatotrophs, producing a physiological GH pulse. Its short half-life preserves the natural pulsatile secretion pattern.

05

Effects reported in research

Reported outcomes, not promises. These come mostly from preclinical (cell or animal) research and have not been confirmed in human trials.

  • Amplified pulsatile GH release
  • Improved sleep architecture
  • Enhanced lipolysis
  • Synergistic with GHRP co-administration
06

Safety & unknowns

Generally well-tolerated. Similar safety profile to sermorelin and CJC-1295 no DAC. Common side effects: flushing, headache, injection site reactions. Preserves natural GH feedback. Not FDA-approved.

Unknowns. No randomized controlled trials in humans have been published, so human safety has not been established in controlled studies.

Informational only — not medical advice. peptidemeta publishes no dosing, protocols, or sourcing. Talk to a qualified clinician about any treatment decision.

07

Studies [1]

  1. Clinical trial 2006

    Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults

    Teichman SL, et al. Journal of Clinical Endocrinology and Metabolism

    Foundational study on the modified GRF platform showing sustained GH stimulation and IGF-1 elevation in human subjects.

    [pubmed]

09

Status sources

Sources behind the tier, regulatory status, sequence and dates on this page.

10

Cite this entry

$ cite --format=apa

peptidemeta. (2026). MOD-GRF (1-29). In peptidemeta: The peptide library, ranked by evidence. Retrieved November 8, 2026, from https://peptidemeta.com/p/mod-grf-1-29/

$ cite --format=bibtex 
@misc{peptidemeta-mod-grf-1-29,
  title = {MOD-GRF (1-29)},
  author = {{peptidemeta}},
  year = {2026},
  howpublished = {\url{https://peptidemeta.com/p/mod-grf-1-29/}},
  note = {Accessed 2026-11-08}
}

Accessed date reflects when you opened this page. Cite primary studies for scientific claims.

esc
↑↓ navigate ↵ open